{
    "2019-07-21": [
        [
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "张金洋团队",
                        "2019Q2",
                        "机构医药持仓",
                        "2+X主线"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}